Materials and reagents Sample Clauses

Materials and reagents. Azobispyridine (apy) and Ru(tpy)Cl3 were synthesized according to the literature methods.8, 14 XxXx, NaClO4 (both Merck), NaClO, AgNO3, (both Acros), tpy (Aldrich) and RuCl3·3H2O (Xxxxxxx & Xxxxxxx) were used as supplied. All other chemicals and solvents were reagent grade commercial materials and used as received, without further purification. C, H and N determinations were performed on a Xxxxxx Xxxxx 2400 Series II analyzer. Mass spectra were obtained with x Xxxxxxxx MAT TSQ-700 mass spectrometer equipped with a custom-made electrospray interface (ESI). FTIR spectra were obtained on a Perkin Xxxxx Xxxxxxx 1000 FTIR spectrophotometer equipped with a Golden Gate ATR device, using the diffuse reflectance technique (res. 4 cm-1). NMR spectra were recorded on a Bruker DPX-300 spectrometer operating at a frequency of 300 MHz, on a Bruker AV-500, at a frequency of 500 MHz, and on a Bruker DMX-400, at a frequency of 400 MHz. Chemical shifts were calibrated against tetramethylsilane (TMS).
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Materials and reagents. 2,2´-azobispyridine (apy), Ru(tpy)Cl3, [Ru(apy)(tpy)Cl](ClO4), [Ru(apy)(tpy)(H2O)](ClO4)2·2H2O, [Ru(apy)(tpy)(CH3CN)](ClO4)2, [Ru(azpy)(tpy)Cl]Cl·5H2O and [Ru(impy)(tpy)Cl](ClO4) were synthesised according to the literature methods.30-32, 34, 35 LiCl, NaClO4 (both Merck), NaClO, AgNO3 (both Acros), tpy (Aldrich), RuCl3·3H2O (Johnson & Matthey), 9-EtGua (Sigma) and H2N(CH2)6NH2 (Fluka) were used as supplied. Ultra pure water (18.2 ΩM; Aldrich) was used for the MS, CD and LD experiments. All other chemicals and solvents were reagent grade, commercial materials and used as received. Calf-thymus DNA (ct-DNA) was purchased from Sigma Aldrich and used without further purification. The solid DNA salt was dissolved in ultra pure water (18.2 ΩM; Aldrich) and left at 278 K for 24 hours to fully hydrate. The resulting stock DNA solution was kept frozen and it was thawed when needed. The concentration of the DNA stock solution was determined spectroscopically, using the known molar extinction coefficient of ct-DNA at 258 nm: ε258 = 6600 molar base−1 cm−1 dm3.36 A 100 mM stock solution of sodium cacodylate buffer (pH 6.8) was prepared, as well as a 1M sodium chloride stock solution, using in both cases ultra pure water (18.2 ΩM; Aldrich). C, H and N determinations were performed on a Perkin Elmer 2400 Series II analyzer. Mass spectra were obtained with a Finnigan Aqa mass spectrometer equipped with an electrospray ionization source (ESI). NMR spectra were recorded on a Bruker DPX-300 spectrometer operating at a frequency of 300 MHz, at a temperature of 310 K, unless otherwise stated. Chemical shifts were calibrated against tetramethylsilane (TMS). CD spectra were collected in 2 mm path-length quartz cuvettes using a Jasco J-810 spectropolarimeter. Flow LD spectra were collected using a flow Couette cell in the above-mentioned spectropolarimeter. All CD and LD spectra were recorded at room temperature. Synthesis and characterization of [{Ru(apy)(tpy)}2{µ-H2N(CH2)6NH2}](ClO4)4 [Ru(apy)(tpy)(H2O)](ClO4)2·2H2O (26 mg, 0.034 mmol) and H2N(CH2)6NH2 (2 mg, 0.016 mmol) were dissolved in 12 mL EtOH abs:MeOH 5:1. The solution was vigorously refluxed for 15 hours. The pH remained constant around 7. The product was collected by filtration, washed with little ethanol and diethyl ether and dried in vacuo over silica. Yield: 20 mg (76%). Anal. Calc. for C56H54N16O16Cl4Ru2: C, 43.4; H, 3.5; N, 14.4%. Found: C, 43.8; H, 3.8; N, 14.5%. m/z (ESI-MS) 634.1 ([{Ru(apy)(tpy)}{H2N(CH2)6NH2}]+...
Sample 1Sample 2
Materials and reagents. Chemicals used for treatments: β-NF, PB, TCPOBOP, 3MC, KA, PCN, dexamethasone (water soluble) were all acquired from Sigma-Xxxxxxx (St. Xxxxx, MO) as well as Xxxxxxxx' E medium, Xxxxx-Xxxxxx buffer, collagenase and other general chemicals. Antibodies to CYP2B1 and CYP3A2 were provided by Xx. Xxxxx Xxxxxxx (University of California, San Diego, CA), and anti-CYP1A antibody was purchased from Daichi Pure Chemicals (Tokyo, Japan). The anti-GAPDH monoclonal antibody was acquired from Millipore (Billereca, MA) and the anti-CAR polyclonal antibody was purchased from Santa Xxxx Biotechnology (Santa Cruz, CA).
Sample 1
Materials and reagents. 2.1.1 Plasticware 1. 5ml Cyrovials™ (Costar corning). 5ml, 10ml and 25ml serological pipettes (Costar corning). 5ml FACs tubes (Beckton Xxxxxxxxx). Syringe filters 0.22μm/0.4μm (Triple Red). ART filter tips, 1000, 250, 20ul (Thermo scientific). Glasstic Slides (Hycor KOVA, distributed by Xxxxxx Scientific, USA). Vacutainer™ tubes (BD, Biosciences, San Jose, CA). 1. 5ml micro-centrifuge (Eppendorf) tubes (VWR, UK). 15ml and 50ml Falcon tubes (Costar corning).
Sample 1
Materials and reagents. ​ i. Commercially available chondrocytes derived from normal and/or OA knee tissue and companion growth mediums. ​ ii. Chondrocyte differentiation mediums. ​ iii. 3D cell culturing matrix. ​ iv. Consumable cell culture ware including plates, pipets, etc. ​ v. Recombinant cytokines for differentiation of cells. ​
Sample 1
Materials and reagents. ​ 1. Bone marrow-derived mesenchymal stem cells (BMMSC). ​
Sample 1
Materials and reagents. 2-pyridinealdazine (paa), 4-amino-3,5-bis(pyridine-2-yl)-1,2,4-triazole (abpt), Ru(tpy)Cl3 and cis-Ru(bpy)2Cl2 were synthesized following procedures described in literature.33-36 2-cyanopyridine, 2-pyridinaldehyde, hydrazine monohydrate, NH4PF6 and tpy (Xxxxxxx), LiCl (Merck), NaBF4 and bpy (Acros) and RuCl3·3H2O (Xxxxxxx & Xxxxxxx) were used as supplied. All other chemicals and solvents were reagent grade commercial materials and used as received, without further purification. C, H and N determinations were performed on a Xxxxxx Xxxxx 2400 Series II analyzer. Mass spectra were obtained with a Xxxxxxxx MAT TSQ-700 mass spectrometer equipped with a custom-made electrospray interface (ESI). NMR spectra were recorded on a Bruker DPX-300 spectrometer operating at a frequency of 300 MHz. Chemical shifts were calibrated against tetramethylsilane (TMS). Synthesis and characterization of [{Ru(tpy)Cl}2(µ-paa)](BF4)2 (1h) LiCl (500 mg, 11.80 mmol) was dissolved in 80 ml of ethanol-water (3:1). Triethylamine (0.160 ml, 1.135 mmol) was added, followed by Ru(tpy)Cl3 (500 mg, 1.135 mmol) and paa (360 mg, 1.715 mmol). The mixture was vigorously refluxed for 90 minutes, and the hot solution was filtered to remove any insoluble material. The brown solution was evaporated to dryness. 15 ml methanol were used to dissolve the residue, to which 35 ml of a methanolic saturated solution of NaBF4 were added. The flask was left for 3 days at 4 °C. A brown precipitate had then appeared, which was filtered, washed with little ice-cold ethanol and ether and dried in vacuo over silica Yield: 39 mg (3%). Anal. Calc. for C42H32N10B2F8Cl2Ru2: C, 44.9; H, 2.9; N, 12.5. Found: C, 42.2; H, 2.9; N, 11.7. m/z (ESIMS) 580.1 ([Ru(paa)(tpy)Cl]+); 475.0 ([{Ru(tpy)Cl}2(μ-paa)]2+). 1H NMR (DMSO-d6): δ (ppm): 9.71 (2H, d, 5.49 Hz, 6P); 8.44 (8H, m, 3T, 3T´); 8.22 (2H, t, 6.93 Hz, 4P); 8.12 (4H, t, 7.12 Hz, 4T); 8.00 (4H, m, 5P, 4T´); 7.92 (2H, d, 8.06 Hz, 3P); 7.46 (4H, t, 6.24 Hz, 5T); 7.11 (4H, d, 4.83 Hz, 6T); 6.97 (2H, s, CH=). Synthesis and characterization of [Xx(abpt)(bpy)2](PF6)2 (1i) The synthesis of [Ru(abpt)(bpy)2](PF6)2 was carried out as described in the literature,32 with slight modifications. cis-Ru(bpy)2Cl2 (75 mg, 0.18 mmol) and abpt (82 mg, 0.34 mmol) were dissolved in 15 ml of ethanol and refluxed for two hours. The mixture was evaporated under reduced pressure, and the obtained residue was dissolved in 2.5 ml methanol. 5 ml of a saturated solution of NH4PF6 were added. An orange-...
Sample 1
AutoNDA by SimpleDocs
Materials and reagents. All chemicals were analytical reagent grade and obtained from Sigma-Xxxxxxx and used as purchased unless otherwise specified. Copper(I) bromide was obtained with g99.995% purity (trace metals basis) from Sigma-Xxxxxxx and stored under vacuum before use. Solvents were obtained from Xxxxxx Scientific. Methacryloxyethyltrimethylammonium chloride (METAC) was obtained as a 75% aqueous solution containing 600 ppm monomethyl ether hydroquinone as inhibitor; the monomer was purified to remove the inhibitor by passing the solution through a basic alumina column (Xxxxxxxxx grade I).
Sample 1

Related to Materials and reagents

  • Materials and Supplies The cost of materials and supplies is allowable. Purchases should be charged at their actual prices after deducting all cash discounts, trade discounts, rebates, and allowances received. Withdrawals from general stores or stockrooms should be charged at cost under any recognized method of pricing, consistently applied. Incoming transportation charges are a proper part of materials and supply costs.

  • MATERIALS AND WORKMANSHIP (a) All equipment, material, and articles incorporated into the work covered by this Agreement shall be new and of the most suitable grade for the purpose intended, unless otherwise specifically provided in this Agreement. (b) Seller shall obtain Company approval of the machinery and mechanical and other equipment to be incorporated into the work. When required by Company, Seller shall also obtain Company's approval of the material or articles which Seller contemplates incorporating into the work. When so directed, Seller shall submit samples for approval at Seller's expense. Machinery, equipment, material, and articles that do not have the required approval shall be installed or used at the risk of subsequent rejection. (c) References in the specifications or drawings to equipment, material, articles, or patented processes by trade name, make, or catalog number, shall be regarded as establishing a standard of quality and shall not be construed as limiting competition. Seller may, with Company's written approval, use any equipment, material, article, or process that is equal to that specified, unless the words "No Substitution" follow the listing of the item in the specifications or drawings. Unless otherwise agreed, modifications due to use of “or equal” supplies, is at Seller’s expense. (d) All work under this Agreement shall be performed in a skillful and workmanlike manner. Company may require, in writing, Seller to remove from the work any employee Company deems incompetent, careless, or otherwise objectionable.

  • Materials and Improvements Title to materials, improvements, and other property required of PURCHASER by this contract shall vest in and become the property of STATE at the time such are furnished by PURCHASER and accepted by STATE. Only materials, improvements, and property free and clear of liens, claims, and encumbrances shall be furnished by PURCHASER. All existing improvements located on State land, and any improvements placed on State land by PURCHASER which become the property of STATE, shall be safeguarded by PURCHASER. If such improvements are injured, damaged, or removed from the areas of operations by PURCHASER or by contractors of PURCHASER, such improvements shall be repaired (or replaced, in the event of removal,) as soon as possible by PURCHASER, without cost to STATE.

  • Materials and Methods 86 2.1 PARTICIPANTS 87 We used baseline measurements from a convenience sample of participants in previous (3) and 88 ongoing cohort studies investigating the effects of rehabilitation on balance responses (Table 1). PD 89 participants were mild-moderate with bilateral symptoms (Xxxxx and Xxxx stage 2-3 (13)). All 90 participants provided written informed consent and all study procedures were approved by Institutional 91 Review Boards at the Georgia Institute of Technology and Emory University.

  • Materials and Equipment ‌ Material means property that may be consumed or expended during performance, component parts of a higher assembly, or items that lose their individual identity through incorporation into an end item. Equipment means a tangible item that is functionally complete for its intended purpose, durable, nonexpendable, and needed for performance. Materials and Equipment shall be priced in accordance with the terms of the task order award, contract type, and applicable FAR and agency-specific regulatory supplements. Unless otherwise directed by task order terms and conditions, the Contractor may apply indirect costs to materials and equipment consistent with the Contractor’s usual accounting practices.

  • MARKETING MATERIALS AND REPRESENTATIONS (a) The Participant represents and warrants that it will not make any representations concerning a Fund, Creation Units or Shares, other than those consistent with the Prospectus or any Marketing Materials (as defined below) furnished to the Participant by the Distributor. (b) The Participant agrees not to furnish, or cause to be furnished by it or its employees, to any person, or to display or publish, any information or materials relating to a Fund or the Shares, including, without limitation, promotional materials and sales literature, advertisements, press releases, announcements, statements, posters, signs or other similar materials (“Marketing Materials”), unless (i) such Marketing Materials: (a) are either furnished to the Participant by the Distributor, or (b) if prepared by the Participant, are consistent in all material respects with the Prospectus, and clearly indicate that such Marketing Materials are prepared and distributed by the Participant, and (ii) Participant and such Marketing Materials prepared by the Participant comply with applicable FINRA rules and regulations. The Participant shall file all such Marketing Materials that it prepares with FINRA, if required by applicable laws, rules or regulations. (c) The Trust represents and warrants that (i) the Prospectus is effective, no stop order of the SEC has been issued, no proceedings for such purpose have been instituted or, to its knowledge, are being contemplated; (ii) the Prospectus conforms in all material respects to the requirements of all applicable law, and the rules and regulations of the SEC thereunder and does not and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; (iii) the Shares, when issued and delivered against payment of consideration thereof, as provided in this Agreement, will be duly and validly authorized, issued, fully paid and non-assessable and free of statutory and contractual preemptive rights, rights of first refusal and similar rights; (iv) no consent, approval, authorization, order, registration or qualification of or with any court or governmental agency or body is required for the issuance and sale of the Shares, except the registration of the Shares under the 1933 Act; (v) Shares will be approved for listing on a national exchange; (vi) it will not lend Fund securities pursuant to any securities lending arrangement that would prevent the Trust from settling a Redemption Order when due; (vii) any and all Marketing Materials prepared by the Trust and provided to the Participant in connection with the offer and sale of Shares shall comply with applicable law, including without limitation, the provisions of the 1933 Act and the rules and regulations thereunder and applicable requirements of FINRA, and will not contain any untrue statement of a material fact related to a Fund or the Shares or omit to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; and (viii) it will not name the Participant in the Prospectus, Marketing Materials, or on the Fund’s website without the prior written consent of Participant, unless such naming is required by law, rule, or regulation. (d) Notwithstanding anything to the contrary in this Agreement, the term Marketing Materials shall not include (i) written materials of any kind that generally mention a Fund without recommending the Fund (including in connection with a list of products sold through Participant or in the context of asset allocations), (ii) materials prepared and used for the Participant’s internal use only, (iii) brokerage communications, including correspondence and institutional communications, as defined under FINRA rules, prepared by the Participant in the normal course of its business, and (iv) research reports; provided, however, that any such materials prepared by Participant comply with applicable FINRA rules and regulations and other applicable laws, rules and regulations.

  • Quality of Materials and workmanship The Contractor shall ensure that the Construction, Materials and workmanship are in accordance with the requirements specified in this Agreement, Specifications and Standards and Good Industry Practice.

  • Materials of Environmental Concern have not been transported or disposed of from the Properties in violation of, or in a manner or to a location which could give rise to liability under, any Environmental Law, nor have any Materials of Environmental Concern been generated, treated, stored or disposed of at, on or under any of the Properties in violation of, or in a manner that could give rise to liability under, any applicable Environmental Law, except insofar as any such violation or liability referred to in this paragraph, or any aggregation thereof, could not reasonably be expected to result in the payment of a Material Environmental Amount.

  • DEVELOPMENTAL REQUIREMENTS The Personal Development Plan (PDP) for addressing developmental gaps is attached as Annexure B.

  • Hazardous Materials Activities, Etc Each Credit Party shall promptly take, and shall cause each of its Subsidiaries promptly to take, any and all actions necessary to (i) cure any violation of applicable Environmental Laws by such Credit Party or its Subsidiaries that could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, and (ii) make an appropriate response to any Environmental Claim against such Credit Party or any of its Subsidiaries and discharge any obligations it may have to any Person thereunder where failure to do so could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!